drugset / Trial / NCT00427050

A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel

NCT00427050

Phase 2 Completed 50 enrolled Peplin
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the optimal tolerated regime of PEP005 for the treatment of actinic keratoses of the face or face and scalp.

Timeline

Start
2007-01
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ingenol mebutate Small molecule Topical

Indications